REFERENCES

Healthcare Professionals
  1. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53(7):1439-1446.
  2. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53(7):1431-1438.
  3. Pappert EJ, Germanson T; Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008;23(4):510-517.
  4. Data on file (MYO-026-1207). Louisville, KY: Solstice Neurosciences, LLC; 2007.
  5. FDA approval letter. MYOBLOC for cervical dystonia. December 8, 2000.
  6. FDA approval letter. Botox for cervical dystonia. December 21, 2000.
  7. Heavner J, Leong M, Royal M. The MIND registry: an observational database of patients treated with botulinum toxin type B (Myobloc®) – pain subset of the database [abstract]. International Conference-Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins; June 23-25, 2005; Denver, CO.
  8. MYOBLOC [package insert]. Louisville, KY: Solstice Neurosciences, LLC; 2010.
  9. Lew MF, Factor SA. Botulinum toxin type B (MYOBLOC) is well-tolerated and efficacious in a long-term observational study: results of an open-label extension trial of repeated dosing in subjects with cervical dystonia. Poster presented at: 58th Annual Meeting of the American Academy of Neurology; April 1-8, 2006; San Diego, CA.
  10. Data on file (MYO-031-0108). Louisville, KY: Solstice Neurosciences, LLC; 2007.
  11. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, eds. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:211-237.
  12. Comella CL, Jankovic J, Shannon KM, et al; Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65:1423-1429.
  13. Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord. 2005;20(9):1152-1160.
  14. Consky ES, Basinki A, Belle L, et al. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability.Neurology. 1990;40(suppl 1):445.
  15. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990;13(4):227-236.
  16. Data on file (MYO-030-1207). Louisville, KY: Solstice Neurosciences, LLC; 2007.
  17. Data on file (MYO-004-0306). Louisville, KY: Solstice Neurosciences, LLC; 2007.
  18. Data on file (MYO-032-0108). Louisville, KY: Solstice Neurosciences, LLC; 2007.
  19. Data on file (MYO-020-0707). Louisville, KY: Solstice Neurosciences, LLC; 2007.
  20. Camfield L, Ben-Shlomo Y,Warner TT; Epidemiological Study of Dystonia in Europe Collaborative Group. Impact of cervical dystonia on quality of life. Mov Disord. 2002;17(4):838-841.
  21. Lew MF. Botulinum toxin type B: an effective treatment for alleviating pain associated with cervical dystonia. J Back Musculoskeletal Rehabil. 2002;16:3-9.
  22. Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord. 1991;6(2):119-126.

See Important Safety Information below.

Circle of Care Provider Portal
Click Here